LLY

764

+2.13%↑

JNJ

176.45

-0.55%↓

ABBV

216.08

-0.77%↓

UNH

339.82

-2.33%↓

AZN

77.61

-0.58%↓

LLY

764

+2.13%↑

JNJ

176.45

-0.55%↓

ABBV

216.08

-0.77%↓

UNH

339.82

-2.33%↓

AZN

77.61

-0.58%↓

LLY

764

+2.13%↑

JNJ

176.45

-0.55%↓

ABBV

216.08

-0.77%↓

UNH

339.82

-2.33%↓

AZN

77.61

-0.58%↓

LLY

764

+2.13%↑

JNJ

176.45

-0.55%↓

ABBV

216.08

-0.77%↓

UNH

339.82

-2.33%↓

AZN

77.61

-0.58%↓

LLY

764

+2.13%↑

JNJ

176.45

-0.55%↓

ABBV

216.08

-0.77%↓

UNH

339.82

-2.33%↓

AZN

77.61

-0.58%↓

Home・Akcijų sąrašas・Zai Lab Ltd ADR

Zai Lab Ltd ADR

Uždarymo kaina

SektoriusSveikatos priežiūra

32.23 1.45

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

31.53

Max

32.42

Pagrindiniai rodikliai
By Trading Economics
Pajamos	7.7M -41M
Pardavimai	3.5M 110M
Pelno marža	-37.032
Darbuotojai	1,869
EBITDA	1.4M -55M

Rekomendacijos
By TipRanks
Rekomendacijos	Stiprus pirkimas
12 mėnesių prognozė	+68.36% upside

Dividendai
By Dow Jones
Kitas uždarbis	2025-11-11

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	-622M 3.6B
Ankstesnė atidarymo kaina	30.78
Ankstesnė uždarymo kaina	32.23

Naujienos nuotaikos

By Acuity

100%

360 / 371 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Very Strong Bearish Evidence

28.13 / 31.12 Palaikymas ir pasipriešinimas

Zai Lab Ltd ADR Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2025-09-16 17:03; UTC

Pagrindinės rinkos jėgos

BrainsWay Shares Rise on FDA Clearance of Major Depressive Disorder Treatment

2025-09-16 16:49; UTC

Pagrindinės rinkos jėgos

Įsigijimai, susijungimai, perėmimai

GD Culture Shares Drop After Deal for Pallas Capital

2025-09-16 16:11; UTC

Pagrindinės rinkos jėgos

Corbus Shares Rise on FDA Fast-Track Designation for Cancer Drug

2025-09-16 23:40; UTC

Rinkos pokalbiai

Nikkei May Decline as Yen Strengthens -- Market Talk

2025-09-16 23:34; UTC

Rinkos pokalbiai

Gold Edges Higher Ahead of FOMC Decision -- Market Talk

2025-09-16 23:20; UTC

Rinkos pokalbiai

Restaurant Brands NZ Can Outperform When Cycle Turns -- Market Talk

2025-09-16 21:10; UTC

Įsigijimai, susijungimai, perėmimai

U.S. Investors, Trump Close In on TikTok Deal With China -- WSJ

2025-09-16 20:51; UTC

Rinkos pokalbiai

U.S. Home Sales, New Home Listings Fall in August -- Market Talk

2025-09-16 20:50; UTC

Rinkos pokalbiai

Energy & Utilities Roundup: Market Talk

2025-09-16 20:50; UTC

Rinkos pokalbiai

Įsigijimai, susijungimai, perėmimai

Basic Materials Roundup: Market Talk

2025-09-16 20:25; UTC

Uždarbis

The AI Trade Has Stocks Near Highs Again. Some Tech Names Remain on the Sidelines -- Barrons.com

2025-09-16 20:24; UTC

Uždarbis

These Stocks Moved the Most Today: Oracle, Tesla, Alphabet, Dave & Buster's, Chipotle, and More -- Barrons.com

2025-09-16 19:19; UTC

Rinkos pokalbiai

U.S. Natural Gas Futures Extend Winning Streak -- Market Talk

2025-09-16 18:52; UTC

Rinkos pokalbiai

Oil Futures Advance on Russia Concerns, Weak Dollar -- Market Talk

2025-09-16 18:44; UTC

Rinkos pokalbiai

Global Equities Roundup: Market Talk

2025-09-16 18:44; UTC

Rinkos pokalbiai

EssilorLuxottica Well-Positioned in Growing Smart-Glasses Market -- Market Talk

2025-09-16 18:40; UTC

Įsigijimai, susijungimai, perėmimai

Details Emerge on U.S.-China TikTok Deal -- WSJ

2025-09-16 18:38; UTC

Rinkos pokalbiai

Meta Seen With Long-Term Opportunity to Lead in Smart Glasses -- Market Talk

2025-09-16 18:19; UTC

Rinkos pokalbiai

Gold Settles at New High Ahead of Fed Decision -- Market Talk

2025-09-16 18:01; UTC

Rinkos pokalbiai

U.S. Dollar Weakness Supports Oil's Gains -- Market Talk

2025-09-16 17:34; UTC

Rinkos pokalbiai

Any Question the Bank of Canada Will Cut Now Look to Have Vanished -- Market Talk

2025-09-16 16:53; UTC

Uždarbis

Software Companies Are Fighting Back With AI. The Stocks Are Still Hurting. -- Barrons.com

2025-09-16 16:20; UTC

Rinkos pokalbiai

Įsigijimai, susijungimai, perėmimai

Basic Materials Roundup: Market Talk

2025-09-16 16:15; UTC

Rinkos pokalbiai

Įsigijimai, susijungimai, perėmimai

Global Commodities Roundup: Market Talk

2025-09-16 16:09; UTC

Rinkos pokalbiai

Įsigijimai, susijungimai, perėmimai

Global Energy Roundup: Market Talk

2025-09-16 16:09; UTC

Rinkos pokalbiai

Įsigijimai, susijungimai, perėmimai

Canada Industry Minister to Meet Mining CEOs on Merger -- Market Talk

2025-09-16 15:35; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2025-09-16 15:35; UTC

Rinkos pokalbiai

Gold Soars Past $3,700 Ahead of Fed Decision -- Market Talk

2025-09-16 15:22; UTC

Rinkos pokalbiai

More Investors Think Dollar is Overvalued in Latest BofA Survey -- Market Talk

2025-09-16 15:21; UTC

Rinkos pokalbiai

Sterling Considered Most Overvalued in Nearly 10 Years -- Market Talk

Akcijų palyginimas

Kainos pokytis

Zai Lab Ltd ADR Prognozė

Kainos tikslas

By TipRanks

68.36% į viršų

12 mėnesių prognozė

Vidutinis 53.74 USD 68.36%

Aukščiausias 69 USD

Žemiausias 39 USD

Remiantis 8 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Zai Lab Ltd ADR kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

8 ratings

Pirkti

Laikyti

Parduoti

Remiantis 8 analitikų, pateikusių Zai Lab Ltd ADR akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Techninis įvertinimas

By Trading Central

28.13 / 31.12Palaikymas ir pasipriešinimas

Recent bearish events outweigh bullish events.

All events are bullish.

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę Zai Lab Ltd ADR

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis. The company also develops Tumor Treating Fields, a portable device for delivery of electric fields; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naïve- or -pretreated cancer patients; Tisotumab vedotin, an antibody drug conjugate; Adagrasib for treating KRAS-G12C-mutated NSCLC, colorectal cancer, and pancreatic cancer; and Bemarituzumab to treat gastric and gastroesophageal junction cancer patients. In addition, it develops Sulbactam/durlobactam, a combination of a beta-lactam antibiotic and a beta-lactamase inhibitor for the treatment of serious infections caused by Acinetobacter; KarXT for the treatment of psychiatric and neurological conditions. It has license and collaboration agreement with Tesaro, Inc. to develop, manufacture, and commercialize niraparib; NovoCure to develop and commercialize Tumor Treating Fields; Deciphera to develop and commercialize ripretinib; Paratek Bermuda Ltd. to develop, manufacture, and commercialize omadacycline; argenx, to develop and commercialize efgartigimod; BMS to develop and commercialize tisotumab vedotin and repotrectinib; Mirati to research, develop, manufacture, and commercialize adagrasib; Amgen to develop and commercialize bemarituzumab; and Innoviva to develop and commercialize Sulbactam-Durlobactam; Karuna to develop and commercialize KarXT; and strategic collaboration with Pfizer for XACDURO. The company was incorporated in 2013 and is headquartered in Shanghai, China.